Xtampza ER (oxycodone) NDC 24510-130

NDC codes

FDA NDC Directory

Product NDC (as listed)24510-130Labeler and product segments. Claims need a package NDC.

Product NDC at billing width24510-0130Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
24510-130-10	24510013010	100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (24510-130-10)Marketed from May 10, 2016
24510-130-20	24510013020	20 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK (24510-130-20)Marketed from May 10, 2016

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Xtampza ERSuffix: ER
Generic name (nonproprietary): oxycodone
Active ingredients: Oxycodone — 27 mg/1
Dosage form: Capsule, Extended release
Route: Oral
Labeler: Collegium Pharmaceutical, Inc.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 208090
Marketing start: May 10, 2016
Listing expires: Dec 31, 2027
DEA schedule: CII
Other FDA classes: Full Opioid Agonists (Mechanism)
Identifiers: Product ID 24510-130_fda0989d-9319-4e35-af83-fca1ec66878eSPL ID fda0989d-9319-4e35-af83-fca1ec66878eSPL set ID b0a5ded2-8ee2-49ca-a86c-2b28ae40f60cRxCUI 1790527, 1790533, 1791558, 1791560, 1791567, 1791569, 1791574, 1791576, 1791580, 1791582UNII CD35PMG570UPC 0324510140101, 0324510115109, 0324510130102
Pharmacologic class: Opioid Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N424510013010 followed by a unit qualifier and the quantity

Package 24510-0130-10. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Dec 30, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

XTAMPZA ER is indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. XTAMPZA ER is an opioid agonist indicated for the management of severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death,which can occur at any dosage or duration and persist over the course of therapy, reserve opioid analgesics, including XTAMPZA ER, for use in patients for whom alternative…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 208090

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 208090
Product	Strength	Form · route	Labeler	Product NDC
Xtampza ERoxycodone	Oxycodone 9 mg/1	Capsule, Extended releaseOral	Collegium Pharmaceutical, Inc.	24510-110
Xtampza ERoxycodone	Oxycodone 13.5 mg/1	Capsule, Extended releaseOral	Collegium Pharmaceutical, Inc.	24510-115
Xtampza ERoxycodone	Oxycodone 18 mg/1	Capsule, Extended releaseOral	Collegium Pharmaceutical, Inc.	24510-120
Xtampza ERoxycodone	Oxycodone 36 mg/1	Capsule, Extended releaseOral	Collegium Pharmaceutical, Inc.	24510-140